The study is designed to assess the efficacy and safety of famciclovir 250 mg bid suppressive treatment in men and women with herpes virus type 2 (HSV-2) infection, with and without reported history of genital herpes and with or without herpes virus type 1 (HSV-1) seropositivity

Condition	Intervention	Phase
Symptomatic genital herpes Asymptomatic genital herpes	Drug: Famciclovir	Phase IV

Further Study Details: 

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

Males or non-pregnant females at least 18 years of age with HSV-2 seropositive serology with or without history of clinically diagnosed recurrent genital herpes

Exclusion Criteria:

Pregnancy History of renal dysfunction Use of immunosuppressive therapy, include steroids (either than topical or inhalated), or use of probenicid Hypersensitivity to famciclovir, valacyclovir or drugs with similar chemical structure

Alabama
      University of Alabama at Birmingham, Birmingham,  Alabama,  35294,  United States
Florida
      Orlando Clinical Research Center, Orlando,  Florida,  32809,  United States
Indiana
      IU Center for Clinical STD Research, Indianapolis,  Indiana,  46202,  United States
North Carolina
      UNC Clinical Research - Raleigh, Raleigh,  North Carolina,  27607,  United States
Oklahoma
      Lynne Health Science Institute, Oklahoma City,  Oklahoma,  73112,  United States
Oregon
      Westover Heights Clinic, Portland,  Oregon,  97210,  United States
Washington
      University of Washington - Virology Research Clinic, Seattle,  Washington,  98122,  United States

Study chairs or principal investigators

Novartis Pharmaceuticals,  Study Chair,  Novartis   

Study ID Numbers:  CFAM810A2404
Last Updated:  August 11, 2005
Record first received:  August 11, 2005
ClinicalTrials.gov Identifier:  NCT00129818
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-08-23